Tranos P, Scott R, Zambarakji H, Ayliffe W, Pavesio C, Charteris D G
Department of Vitreoretinal Surgery, Moorfields Eye Hospital, London, EC1V 2PD, UK.
Br J Ophthalmol. 2006 Sep;90(9):1107-10. doi: 10.1136/bjo.2006.092965. Epub 2006 May 24.
To evaluate the efficacy of pars plana vitrectomy (PPV) in the management of chronic uveitic cystoid macular oedema (CMO).
A prospective, interventional, randomised, controlled, pilot study. 23 eyes of 23 patients with CMO secondary to chronic intermediate or posterior uveitis unresponsive to medical treatment were randomised into a surgical (group S) or medical group (group M). 12 patients in group S underwent PPV as opposed to 11 patients in group M who received systemic corticosteroid and/or immunosuppressive treatment during the study period. The primary outcome measures of the study were change in visual acuity and angiographic appearance of CMO at 6 months.
Mean visual acuity in group S improved significantly from 1.0 (0.62) at baseline to 0.55 (0.29) at 6 months following vitrectomy (p = 0.011), with five (42%) eyes reaching vision of 20/40 or better. Conversely, mean visual acuity in group M improved only marginally by 0.03 (0.27) (p = 0.785). CMO after vitrectomy was angiographically improved in four (33%) eyes, remained unchanged in seven (58%) eyes, and deteriorated in one (8%) eye. In the medical group, fluorescein leakage decreased in one eye, did not alter in four eyes, and deteriorated in two eyes.
PPV for macular oedema secondary to chronic uveitis despite angiographic improvement in only one third of the patients, seems to have a significant beneficial effect on visual function. This study provides enough evidence to justify a large scale trial which would define the role of vitrectomy in uveitic macular oedema.
评估玻璃体切除术(PPV)治疗慢性葡萄膜炎性黄斑囊样水肿(CMO)的疗效。
一项前瞻性、干预性、随机、对照的试点研究。将23例因慢性中间葡萄膜炎或后葡萄膜炎导致CMO且药物治疗无效的患者的23只眼随机分为手术组(S组)和药物组(M组)。S组12例患者接受了PPV,而M组11例患者在研究期间接受了全身糖皮质激素和/或免疫抑制治疗。该研究的主要观察指标为6个月时的视力变化和CMO的血管造影表现。
S组平均视力从基线时的1.0(0.62)显著提高到玻璃体切除术后6个月时的0.55(0.29)(p = 0.011),5只眼(42%)视力达到20/40或更好。相反,M组平均视力仅略有提高0.03(0.27)(p = 0.785)。玻璃体切除术后,血管造影显示4只眼(33%)的CMO有所改善,7只眼(58%)保持不变,1只眼(8%)恶化。在药物组中,1只眼的荧光素渗漏减少,4只眼未改变,2只眼恶化。
尽管只有三分之一的患者血管造影有所改善,但玻璃体切除术治疗慢性葡萄膜炎继发的黄斑水肿似乎对视觉功能有显著的有益影响。本研究提供了足够的证据来证明进行大规模试验的合理性,该试验将确定玻璃体切除术在葡萄膜炎性黄斑水肿中的作用。